TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37661670

Group type: EXPERIMENTAL
Intervention: Tracheostomy opening
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Tracheostomy closure
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Accidental decannulation (early complication)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Aspiration pneumonia (late complication)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Subglottic stenosis (late complication)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Accidental decannulation (late complication)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Suprastomal collapse (late complication)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Tracheocutaneous fistula (late complication)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Granulation tissue (late complication)
Number of subjects: 26
Study: 37661830

Group type: EXPERIMENTAL
Intervention: Automatic scoring of home polygraphy (PG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Manual scoring of home polygraphy (PG)
Number of subjects: 54
Study: 37662485

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37662520

Group type: EXPERIMENTAL
Intervention: Parsaclisib 20 mg once daily for 8 weeks then 2.5 mg QD (daily dosing group [DG])
Number of subjects: 126

Group type: COMPARATOR
Intervention: Parsaclisib 20 mg once daily for 8 weeks then 20 mg once weekly (weekly dosing group [WG])
Number of subjects: 126
Study: 37662589

Group type: EXPERIMENTAL
Intervention: Bioengineered human acellular vessels (HAVs)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Commercial expanded polytetrafluoroethylene (ePTFE) grafts
Number of subjects: 355
Study: 37662595

Group type: EXPERIMENTAL
Intervention: sucrosomial Vitamin D3 (200,000 IU weekly)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Vitamin D3 treatment (not specified)
Number of subjects: 25
Study: 37662597

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Mediterranean diet with beetroot juice (BJ + MeD)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MeD)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control
Number of subjects: 180
Study: 37663034

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 218
Study: 37663146

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 20
Study: 37663201

Group type: EXPERIMENTAL
Intervention: METS-VF
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: WC
Number of subjects: 185

Group type: COMPARATOR
Intervention: ABSI
Number of subjects: 185

Group type: COMPARATOR
Intervention: VAI
Number of subjects: 185

Group type: COMPARATOR
Intervention: WHR
Number of subjects: 185

Group type: COMPARATOR
Intervention: BMI
Number of subjects: 185

Group type: COMPARATOR
Intervention: BRI
Number of subjects: 185

Group type: COMPARATOR
Intervention: LAP
Number of subjects: 185
Study: 37663359

Group type: EXPERIMENTAL
Intervention: Synchronous telerehabilitation program with a neuropsychologist, nutritionist, and physiotherapist for 6 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Informative booklet and weekly phone calls for 6 weeks
Number of subjects: 26
Study: 37663593

Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment (EA) using sacral acupoints
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment (EA) using abdominal acupoints
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment (EA) using alternating acupoints
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment (EA)
Number of subjects: 360
Study: 37663954

Group type: EXPERIMENTAL
Intervention: FiApp smartphone-based application for self-monitoring fluid intake
Number of subjects: 25
Study: 37664025

Group type: EXPERIMENTAL
Intervention: Lenvatinib (20 mg/day) plus Pembrolizumab (200 mg every 3 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunitinib (50 mg/day, 4 weeks on, 2 weeks off)
Number of subjects: 0
Study: 37664409

Group type: EXPERIMENTAL
Intervention: Calcium-omics model with modified synthetic down sampling and up sampling
Number of subjects: 2457

Group type: COMPARATOR
Intervention: Agatston scoring
Number of subjects: 2457
Study: 37664485

Group type: EXPERIMENTAL
Intervention: Naloxegol 25mg
Number of subjects: 1337

Group type: EXPERIMENTAL
Intervention: Naloxegol 12.5mg
Number of subjects: 1337

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 1337
Study: 37664560

Group type: EXPERIMENTAL
Intervention: Standard pfCa monitoring (aiming pfCa level of 0.25-0.35 mmol/L)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No pfCa monitoring (constant citrate infusion at 4 mmol/L)
Number of subjects: 50
Study: 37664999

Group type: EXPERIMENTAL
Intervention: 3-month training programme designed to improve endurance
Number of subjects: 5
Study: 37665178

Group type: EXPERIMENTAL
Intervention: Selinexor 40 mg/m2 with mitoxantrone, etoposide, and cytarabine (MEC)
Number of subjects: 23
Study: 37665397

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.15 µg kg continuous intravenous infusion)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Midazolam (control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 24
Study: 37665472

Group type: EXPERIMENTAL
Intervention: Turkish version of the Diabetes Eating Problem Survey-Revised (DEPS-R)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EDE-Q
Number of subjects: 100
Study: 37665497

Group type: EXPERIMENTAL
Intervention: Preservative-free oxybuprocaine hydrochloride 0.4% unit-dose eye drops, five times daily postoperatively until complete epithelial healing
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sodium hyaluronate 0.2%
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 72
Study: 37665565

Group type: EXPERIMENTAL
Intervention: Governmental non-pharmaceutical interventions (NPI's)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: COVID-19 Stringency Index
Number of subjects: 19
Study: 37665622

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement System for PrEP Uptake and Adherence (MES-PrEP) and motivational text messaging (MTM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard PrEP counseling
Number of subjects: 120
Study: 37665777

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Avelumab plus Pegylated Liposomal Doxorubicin (PLD)
Number of subjects: 566

Group type: COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin (PLD)
Number of subjects: 566
Study: 37665832

Group type: EXPERIMENTAL
Intervention: Physical activity (PA) counselling
Number of subjects: 14
Study: 37665877

Group type: EXPERIMENTAL
Intervention: Individualized pleasure-oriented exercise sessions with enhancements for promoting pleasure (individualization based on preference and tolerance, self-regulation of intensity, repeated assessments of core affect)
Number of subjects: 46

Group type: COMPARATOR
Intervention: General American College of Sports Medicine exercise prescription
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Individualized pleasure-oriented exercise sessions
Number of subjects: 46
Study: 37666262

Group type: EXPERIMENTAL
Intervention: Nutrition education interventions (nutrition information during flag ceremonies, classroom lessons, school club meetings, peer group mentoring, BMI measurement and counselling, and parent-teacher meetings) for 4 months.
Number of subjects: 536

Group type: COMPARATOR
Intervention: Control group (standard academic curriculum on health and nutrition).
Number of subjects: 536
Study: 37666264

Group type: EXPERIMENTAL
Intervention: Regorafenib combined with nivolumab and FOLFOX chemotherapy
Number of subjects: 39
Study: 37666383

Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 37666539

Group type: EXPERIMENTAL
Intervention: Olvimulogene nanivacirepvec (Olvi-Vec) followed by platinum-doublet chemotherapy and bevacizumab
Number of subjects: 186

Group type: COMPARATOR
Intervention: Platinum-doublet chemotherapy and bevacizumab
Number of subjects: 186
Study: 37666548

Group type: EXPERIMENTAL
Intervention: Salpingectomy
Number of subjects: 968

Group type: COMPARATOR
Intervention: Tubal ligation
Number of subjects: 968
Study: 37666557

Group type: EXPERIMENTAL
Intervention: Self-directed learning with an integrated learning video
Number of subjects: 224

Group type: COMPARATOR
Intervention: Traditional teacher-led workshop
Number of subjects: 224
Study: 37666656

Group type: EXPERIMENTAL
Intervention: eCura scoring system
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: W-eCura scoring system
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Positive vertical margin, lymphatic invasion, and younger age
Number of subjects: 314
Study: 37666695

Group type: EXPERIMENTAL
Intervention: Artificial Invaplex (Invaplex)
Number of subjects: 0
Study: 37666709

Group type: EXPERIMENTAL
Intervention: Standardized protocol for diagnosing NTM-PD in pwCF
Number of subjects: 0
Study: 37666816

Group type: EXPERIMENTAL
Intervention: Personalized postprandial glucose-targeting diet
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard of care Mediterranean diet
Number of subjects: 200
Study: 37667204

Group type: EXPERIMENTAL
Intervention: High dose primaquine
Number of subjects: 2336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2336
Study: 37667207

Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block (TPVB) for postoperative analgesia after video-assisted thoracoscopic surgery (VATS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37667213

Group type: EXPERIMENTAL
Intervention: L-PRF + Collagen Membrane (CM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open Flap Debridement (OFD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: L-PRF
Number of subjects: 30
Study: 37667379

Group type: EXPERIMENTAL
Intervention: Advanced respiratory mechanics assessments (including esophageal pressure measurements and complete airway closure detection)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Basic assessments
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: End-expiratory esophageal pressure measurements
Number of subjects: 149
Study: 37667407

Group type: EXPERIMENTAL
Intervention: MyRelief educational platform
Number of subjects: 0
Study: 37667507

Group type: EXPERIMENTAL
Intervention: HLA fully-mismatched sibling-derived CD7 CAR-T therapy
Number of subjects: 1
Study: 37667525

Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure (SBP)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Coefficient of variation of diastolic blood pressure (DBP CV)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: DBP CV
Number of subjects: 382
Study: 37667842

Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Thulium laser enucleation of the prostate (ThuLEP)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Bipolar transurethral enucleation of the prostate (B-TUEP)
Number of subjects: 155
Study: 37667847

Group type: EXPERIMENTAL
Intervention: 9-valent human papillomavirus (9vHPV) vaccine
Number of subjects: 1272
Study: 37667968

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 37668075

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Weighted vest use
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 24
Study: 37668173

Group type: EXPERIMENTAL
Intervention: Tenapanor 50 mg twice a day for up to 39 weeks (for T3MPO-1 completers) or 26 weeks (for T3MPO-2 completers)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Tenapanor 50 mg twice a day for ≥52 weeks
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Tenapanor 50 mg twice a day
Number of subjects: 312
Study: 37668277

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline placebo infusion
Number of subjects: 36
Study: 37668289

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 or 300 mg, either every 4 weeks or every 8 weeks, with up-titration permitted after on-treatment flares (maximum dose: 300 mg q4w)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 or 300 mg
Number of subjects: 53
Study: 37668523

Group type: EXPERIMENTAL
Intervention: IDH 1-mutant 1p/19q codeleted gliomas
Number of subjects: 0

Group type: COMPARATOR
Intervention: IDH 1-mutant noncodeleted gliomas
Number of subjects: 0
Study: 37668539

Group type: EXPERIMENTAL
Intervention: Automobile passive keyless entry (PKE) system activation
Number of subjects: 102
Study: 37668619

Group type: EXPERIMENTAL
Intervention: Intensive BP management (systolic BP target <140 mm Hg; n=155)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Conventional BP management (systolic BP target 140-180 mm Hg; n=150)
Number of subjects: 306
Study: 37668620

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure target <140 mm Hg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure target <160 mm Hg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Systolic blood pressure target ≤180 mm Hg
Number of subjects: 120
Study: 37668621

Group type: EXPERIMENTAL
Intervention: Eye-tracking measurement of social visual engagement
Number of subjects: 499
Study: 37668666

Group type: EXPERIMENTAL
Intervention: Dexcom G6 Pro CGM
Number of subjects: 53

Group type: COMPARATOR
Intervention: Blood Glucose Meter (BGM)
Number of subjects: 53
Study: 37668788

Group type: EXPERIMENTAL
Intervention: Recent anticoagulation in patients with no history of TE
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Recent anticoagulation in patients with history of TE
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: No recent anticoagulation in patients with history of TE
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: ≥30% GPI-negative granulocytes (≥30% to <50%)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: ≥30% GPI-negative granulocytes (≥50%)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: LDH ratio ≥1.5×ULN with ≥2 HDA criteria (2-3 criteria)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: LDH ratio ≥1.5×ULN with ≥4 HDA criteria
Number of subjects: 246
Study: 37668888

Group type: EXPERIMENTAL
Intervention: Tirzepatide (5, 10 or 15 mg)
Number of subjects: 0
Study: 37668898

Group type: EXPERIMENTAL
Intervention: AK120 600 mg single ascending dose (SAD) in healthy subjects
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: AK120 multiple ascending doses (300 mg Q2W, 300 mg QW, 150 mg QW, 75 mg QW) in subjects with AD
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned in the abstract)
Number of subjects: 81
Study: 37669055

Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37669277

Group type: EXPERIMENTAL
Intervention: Pharmaceutical education about the correct use of antibiotic/s
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 0
Study: 37669281

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) plus Supported Protocolized Discontinuation (SPD)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Supported Protocolized Discontinuation (SPD) alone
Number of subjects: 119
Study: 37669289

Group type: EXPERIMENTAL
Intervention: VMood digital intervention delivered via smartphone app for a 3-month period with online support from social workers.
Number of subjects: 336

Group type: COMPARATOR
Intervention: Limited version of the VMood app provided to control group participants until they transition to the intervention group.
Number of subjects: 336
Study: 37669307

Group type: EXPERIMENTAL
Intervention: HB0017 300 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HB0017 (50 mg, 150 mg, 300 mg, 450 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: HB0017 (150 mg, 300 mg, 450 mg)
Number of subjects: 10
Study: 37669480

Group type: EXPERIMENTAL
Intervention: Selinexor (80 mg oral, once weekly)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study: 37669709

Group type: EXPERIMENTAL
Intervention: Increasing social support (measured by SFWB scores)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unchanged social support (measured by SFWB scores)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decreasing social support (measured by SFWB scores)
Number of subjects: 0
Study: 37669739

Group type: EXPERIMENTAL
Intervention: First-trimester ultrasound scan
Number of subjects: 128

Group type: COMPARATOR
Intervention: Second-trimester ultrasound scan
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: First-trimester ultrasound plus a second-trimester ultrasound
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: First-trimester ultrasound scans
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: First-trimester ultrasound participants
Number of subjects: 128
Study: 37669842

Group type: EXPERIMENTAL
Intervention: Economic factors (specifically transportation costs)
Number of subjects: 1496

Group type: EXPERIMENTAL
Intervention: Monthly medication costs
Number of subjects: 1496

Group type: EXPERIMENTAL
Intervention: Suboptimal medication adherence
Number of subjects: 1496
Study: 37669913

Group type: EXPERIMENTAL
Intervention: Bone shielding concept
Number of subjects: 26

Group type: COMPARATOR
Intervention: Dual-zone (DZ) technique
Number of subjects: 26
Study: 37670005

Group type: EXPERIMENTAL
Intervention: Combination of glucose and high-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 5639

Group type: EXPERIMENTAL
Intervention: Combination of glucose and high-sensitivity cardiac troponin I (hs-cTnI)
Number of subjects: 5639

Group type: COMPARATOR
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) alone
Number of subjects: 5639

Group type: COMPARATOR
Intervention: High-sensitivity cardiac troponin I (hs-cTnI) alone
Number of subjects: 5639

Group type: EXPERIMENTAL
Intervention: Dual-marker strategy (glucose < 7 mmol/L and hs-cTnT < 5/hs-cTnI < 4 ng/L)
Number of subjects: 5639

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 5639

Group type: EXPERIMENTAL
Intervention: Cutoff approach combining glucose and hs-cTn
Number of subjects: 5639
Study: 37670171

Group type: EXPERIMENTAL
Intervention: Ambulatory COVID-19 survey (n=906)
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: Observational cohort (n=108)
Number of subjects: 1014

Group type: EXPERIMENTAL
Intervention: Cluster of predominantly young, female, comorbidity-free convalescents with persistent OD and taste disorders
Number of subjects: 1014
Study: 37670194

Group type: EXPERIMENTAL
Intervention: Early drain removal (EDR) on postoperative day 3 if serous and drain bilirubin level < 3 mg/dl (3×3 rule)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Routine drain removal (RDR) based on drain output being serous and < 100 ml
Number of subjects: 108
Study: 37670234

Group type: EXPERIMENTAL
Intervention: Multivariate mixed model approach using clinical diagnosis information as a reference to estimate latent disease time.
Number of subjects: 2186

Group type: EXPERIMENTAL
Intervention: CSF markers of tau proteins accumulation.
Number of subjects: 2186

Group type: EXPERIMENTAL
Intervention: Markers of brain atrophy.
Number of subjects: 2186

Group type: EXPERIMENTAL
Intervention: Individual characteristics (e.g., CSF level of A[Formula: see text]).
Number of subjects: 2186
Study: 37670324

Group type: EXPERIMENTAL
Intervention: DeepCARS™
Number of subjects: 55083

Group type: COMPARATOR
Intervention: Conventional methods (MEWS, NEWS)
Number of subjects: 55083
Study: 37670337

Group type: EXPERIMENTAL
Intervention: P2Et extract from Caesalpinia spinosa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37670340

Group type: EXPERIMENTAL
Intervention: Patients discussing sexual health with healthcare providers (HCPs)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Patients' preferences for discussing sexual health
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Use of digital information tools for sexual health
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Proactive approach of HCPs in sexual health discussions
Number of subjects: 119
Study: 37670376

Group type: COMPARATOR
Intervention: Flat, macroporous mesh with fixation using histoacryl glue (Control)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Anatomically shaped, standard-weight mesh without fixation
Number of subjects: 83
Study: 37670579

Group type: EXPERIMENTAL
Intervention: Ciprofibrate 100 mg/d for 5 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo for 5 weeks
Number of subjects: 10
Study: 37670901

Group type: EXPERIMENTAL
Intervention: HP-β-CD 1500 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HP-β-CD 2000 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HP-β-CD 2500 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HP-β-CD (all doses)
Number of subjects: 12
Study: 37671152

Group type: EXPERIMENTAL
Intervention: ZR-CHOP (zanubrutinib plus R-CHOP)
Number of subjects: 26
Study: 37671176

Group type: EXPERIMENTAL
Intervention: Cluster 1 (Concerned optimists)
Number of subjects: 1552

Group type: COMPARATOR
Intervention: Cluster 2 (Unconcerned confident)
Number of subjects: 1552
Study: 37671264

Group type: EXPERIMENTAL
Intervention: Lysophosphatidylcholine (LPC)-rich structured lipid powder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37671551

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 5050
Study: 37671601

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 6324
Study: 37671609

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 14520